Honz Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021
April 28, 2021 at 04:14 pm
Share
Honz Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 186.023 million compared to CNY 170.227 million a year ago. Operating loss was CNY 28.560 million compared to CNY 13.476 million a year ago. Net loss was CNY 29.878 million compared to CNY 11.466 million a year ago. Basic loss per share from continuing operations was CNY 0.0664 compared to CNY 0.0255 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.